Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
697hyaXPRcUdrmjd
Listen
